CiPA Phase 1 ECG Biomarker Validation Study

Summary

CiPA Phase 1 ECG Biomarker Validation Study is a clinical trial^[1].

Key Facts

• CiPA Phase 1 ECG Biomarker Validation Study is in the country of United States^[2].
• CiPA Phase 1 ECG Biomarker Validation Study's instance of is recorded as clinical trial^[3].
• CiPA Phase 1 ECG Biomarker Validation Study's start time is recorded as +2017-03-14T00:00:00Z^[4].
• CiPA Phase 1 ECG Biomarker Validation Study's end time is recorded as +2017-06-26T00:00:00Z^[5].
• CiPA Phase 1 ECG Biomarker Validation Study's sponsor is recorded as Food and Drug Administration (FDA): Overview and Issues^[6].
• CiPA Phase 1 ECG Biomarker Validation Study's main subject is recorded as long QT syndrome^[7].
• CiPA Phase 1 ECG Biomarker Validation Study's number of participants is recorded as {'unit': '1', 'amount': '+57'}^[8].
• CiPA Phase 1 ECG Biomarker Validation Study's title is recorded as Comprehensive in Vitro Proarrhythmia Assay (CiPA) Clinical Phase 1 ECG Biomarker Validation Study (CiPA Phase 1 ECG Biomarker Study)^[9].
• CiPA Phase 1 ECG Biomarker Validation Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• CiPA Phase 1 ECG Biomarker Validation Study's ClinicalTrials.gov ID is recorded as NCT03070470^[11].
• CiPA Phase 1 ECG Biomarker Validation Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+50'}^[12].
• CiPA Phase 1 ECG Biomarker Validation Study's research intervention is recorded as ritonavir^[13].
• CiPA Phase 1 ECG Biomarker Validation Study's research intervention is recorded as lopinavir^[14].
• CiPA Phase 1 ECG Biomarker Validation Study's research intervention is recorded as chloroquine^[15].
• CiPA Phase 1 ECG Biomarker Validation Study's research intervention is recorded as ranolazine^[16].
• CiPA Phase 1 ECG Biomarker Validation Study's research intervention is recorded as verapamil^[17].
• CiPA Phase 1 ECG Biomarker Validation Study's research intervention is recorded as diltiazem^[18].
• CiPA Phase 1 ECG Biomarker Validation Study's research intervention is recorded as dofetilide^[19].
• CiPA Phase 1 ECG Biomarker Validation Study's research intervention is recorded as Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites^[20].
• CiPA Phase 1 ECG Biomarker Validation Study's clinical trial phase is recorded as phase I clinical trial^[21].
• CiPA Phase 1 ECG Biomarker Validation Study's research subject recruitment status is recorded as completed^[22].
• CiPA Phase 1 ECG Biomarker Validation Study's study type is recorded as interventional study^[23].